-
GLT-1, CB1-CREB Signaling, and TBI Cognition
2026-08-12
A 2025 Biomolecules study identifies an astrocyte-centered mechanism linking post-traumatic 2-AG elevation to GLT-1 loss, glutamate excitotoxicity, neuronal apoptosis, and cognitive dysfunction. Using CB1 pharmacology, behavioral testing, TUNEL, Western blotting, and immunofluorescence, the authors show that restoring GLT-1 or inhibiting CB1-CREB signaling may reduce secondary injury in mice.
-
AM 281: CB1 Cannabinoid Receptor Antagonist
2026-08-11
AM 281 is a selective CB1 cannabinoid receptor antagonist and inverse agonist with a reported CB1 Ki of 12 nM. Its receptor selectivity, defined chemical identity, and use in mouse CB1-CREB-GLT-1 studies make it a practical probe for memory impairment research and neuropharmacology workflows.
-
STMN2 Loss Under Stress in ALS: Translation and Granules
2026-08-11
This reference study identifies TDP-43-independent routes to STMN2 protein depletion in amyotrophic lateral sclerosis models, linking proteasomal degradation, phosphorylation, translation repression, and stress granules. Its comparative neuronal experiments also reveal stress-sensitive STMN2 homeostasis and an RNA-based compensatory response that varies by ALS subtype and CNS region.
-
CTP Solution and the Next Wave of mRNA-LNP Translation
2026-08-10
A mechanistic and translational analysis of how CTP Solution supports IVT mRNA workflows, using intravesical p21 mRNA-LNP therapy for bladder cancer as a case study in connecting nucleotide quality, localized delivery, and therapeutic development.
-
TG003 Cdc2-like Kinase Inhibitor Guide
2026-08-09
TG003 is a selective Cdc2-like kinase inhibitor that targets Clk1, Clk2, and Clk4 with nanomolar reported potency. It provides a research tool for alternative splicing modulation, while ovarian cancer evidence supports CLK2 as a platinum-resistance mechanism rather than establishing TG003 as a cancer treatment.
-
NPC2, Cholesterol, and Ferroptosis in Glioblastoma
2026-08-08
The reference study identifies NPC2 as a clinically associated regulator of glioblastoma behavior and connects its depletion to reduced GPX4 expression, providing a mechanistic link between cholesterol handling and ferroptosis resistance. The findings support NPC2 as a tentative prognostic biomarker and therapeutic research target, while highlighting the need for broader validation across models.
-
Mtb Hijacks BMX to Block Lysosomal Acidification
2026-08-07
This study identifies a host-pathogen mechanism in which Mycobacterium tuberculosis secretes Chp2/Rv1184 to promote BMX-dependent phosphorylation of ATP6V1E1, weakening V-ATPase assembly and lysosomal acidification. The findings connect a bacterial effector, a host tyrosine kinase, and phagolysosome function, while supporting BMX inhibition as a possible host-directed strategy against intracellular tuberculosis.
-
Optimizing Tissue Viability Assays with Tetrazolium (chlorid
2026-08-07
This article addresses real laboratory challenges in cell viability and tissue ischemia assays, demonstrating how Tetrazolium (chloride) (SKU C5688) enables accurate, reproducible quantification of mitochondrial function and viability. Drawing from recent literature and comparative workflows, researchers gain actionable insights into assay optimization and product selection for reliable experimental outcomes.
-
CTOP: Precision μ-Opioid Receptor Antagonist for Neuropharma
2026-08-06
CTOP sets the standard for dissecting μ-opioid receptor signaling in pain and neuropharmacology research, offering unmatched selectivity and workflow flexibility. Discover protocol-driven insights and troubleshooting strategies that unlock the full experimental potential of this potent μ-opioid receptor antagonist.
-
Fosinopril Pharmacokinetics: Dual Elimination and ACE Inhibi
2026-08-06
This review details the innovation of fosinopril as a third-generation ACE inhibitor, highlighting its unique phosphinic acid moiety, dual renal-hepatic elimination, and stable pharmacokinetics in patients with renal dysfunction. These features position fosinopril as a robust tool for hypertension and cardiovascular disease modeling, with practical implications for preclinical and translational research.
-
Concentration-Dependent Cardiovascular Effects of Olive Oil
2026-08-05
This study provides mechanistic insight into how the concentration of olive oil polyphenols, especially hydroxytyrosol, determines their antioxidant, anti-inflammatory, and anti-atherogenic efficacy in cellular models relevant to cardiovascular health. The findings clarify the importance of polyphenol content and support assay optimization for cardiovascular research.
-
Trametinib (GSK1120212): Overcoming Resistance in Oncology R
2026-08-05
Explore how Trametinib (GSK1120212) uniquely addresses EGFR inhibitor resistance through MEK-ERK pathway suppression, advancing oncology research. This article provides a distinctive, evidence-driven perspective beyond standard MEK inhibition protocols.
-
BMX-IN-1: Precision BMX Kinase Inhibition for Host-Pathogen
2026-08-04
Discover how BMX-IN-1, a highly selective BMX kinase inhibitor, uniquely advances both host-pathogen and cancer research by targeting pivotal signaling pathways. This article provides an in-depth analysis of BMX-IN-1’s molecular mechanism, protocol insights, and practical implications beyond existing literature.
-
Nelfinavir Mesylate: Applied HIV-1 Protease Inhibitor Workfl
2026-08-04
Nelfinavir Mesylate enables precise HIV-1 protease inhibition and now serves as a versatile probe in ferroptosis research. This article details optimized workflows, cross-domain applications, and troubleshooting strategies that unlock the full experimental potential of this antiretroviral compound.
-
Ridaforolimus (Deforolimus): Applied mTOR Inhibition in Canc
2026-08-03
Ridaforolimus (Deforolimus, MK-8669) empowers researchers with nanomolar-precision inhibition of mTOR signaling, unlocking reproducible antiproliferative and anti-angiogenic effects in diverse cancer and senescence models. This guide distills actionable workflows, protocol enhancements, and troubleshooting strategies—grounded in recent machine learning-enabled senolytic discovery and validated by rigorous benchmarks.